To hear Wall Street tell it, AbbVie Inc. (NYSE: ABBV) drove right into a ditch last month.
Here’s the thing. The company announced results of a Phase 2 trial on March 22 that were disappointing but hardly fatal. The results mean AbbVie won’t seek fast-track approval for its promising antibody-drug conjugate, Rova-T, but it still expects to be able to take it to market in the near future.
Wall Street overreacted – no surprise there – and AbbVie shares lost 15% in three sessions.
Here’s the thing. Wall Street’s overreaction to AbbVie’s disappointing U.S. Food and Drug Administration trial results weren’t the only reason for its share-price plummet.
You see, though it shouldn’t be, biotech is in the dog house – and investors are primed to punish stocks in the sector for just about anything.
In fact, since hitting a three-year high in August 2015, the Nasdaq Biotech Index is off 6%. During that stretch, the S&P 500 is up nearly 35%.
Biotech is down for three main reasons. Wall Street is worried about…
We’re coming up on the fourth anniversary of a very important conversation we I had regarding the direction of the markets.
Back in late June 2014, I wrote to tell you not to cash out of the market just because it had hit new highs. I quite clearly said I thought we were in the midst of a generational bull market – and the last thing you’d want to do is sit on the sidelines.
Well, what was true then is even truer now. And I can prove why…
See, while the mainstream media has been blasting you with negative headlines about scandals and wars, I’ve been drilling down – looking into the details about what’s really going on.
And here’s something very important I found.
Despite a 10% drop in the markets (a correction), all the volatility we’ve seen since then, rising interest rates, scandals surrounding Facebook Inc. (Nasdaq: FB) and Amazon.com Inc. (Nasdaq: AMZN), and worries about a possible trade war China, first-quarter initial public offerings (IPOs) had their best performance since 2015.
That’s just not something you hear much about amid the general doom and gloom.
But it’s crucial.
See, nothing keeps a bull market on a long-term uptrend better than fresh cash flowing in. And IPOs are Wall Street’s best lure for attracting new money from investors.
With that in mind, let’s look at why need to look at these setbacks not as roadblocks – but as great buying opportunities…
